Unlock instant, AI-driven research and patent intelligence for your innovation.

Use of butin and derivatives thereof for preparing drugs having inhibitive effect on immune system

A technology for the immune system and its derivatives, which is applied in the field of application of buteanin and its derivatives in the preparation of drugs with the effect of suppressing the immune system, and can solve the problems of unclear active ingredients of Vernonia anthelmintic

Inactive Publication Date: 2009-10-21
尚靖
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But so far the active ingredients in Vernonia anthelmintic are still unclear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of butin and derivatives thereof for preparing drugs having inhibitive effect on immune system
  • Use of butin and derivatives thereof for preparing drugs having inhibitive effect on immune system
  • Use of butin and derivatives thereof for preparing drugs having inhibitive effect on immune system

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0020] In Vitro Pharmacodynamics Study of Experimental Example 1 Butacein

[0021] Due to the impairment of pigment cells and their functions in skin lesions of patients with vitiligo, we studied the effect of butycin on human melanocytes cultured in vitro.

[0022] 1.1. Experimental scheme

[0023] 1.1.1 Screening model: normal human melanocytes;

[0024] 1.1.2. Source: redundant foreskin from circumcision of children, without infection.

[0025] 1.1.3. Culture conditions: take normal children’s foreskin and trypsinize it to obtain melanocytes, add bFGF, CT, TPA, FCS, double antibody and other factors to DMEM medium, 5% CO 2 , cultured at 37°C for 7 days and subcultured, the subcultured cells were cultured under the above conditions for 48 hours, and then different concentrations of drugs and controls were added to determine the relevant analysis indicators.

[0026] 1.1.4. Determination method: MTT method for cell proliferation; Dopa staining method for tyrosinase activit...

experiment example 2

[0046] Experimental example 2. In vivo pharmacodynamics study of butycin

[0047] The effect of butycin on the proportion of melanocytes in the basal layer of brown guinea pigs was observed by intragastric administration.

[0048] 2.1. Experimental scheme

[0049] Experimental animals: British short-haired brown guinea pigs, provided by Xinjiang Experimental Animal Center.

[0050] Test drug settings:

[0051] Butein:

[0052] High concentration group: 8.74mg / kg (calculated on the basis of 1 / 25 of the maximum tolerated dose)

[0053] Medium concentration group: 4.37mg / kg (calculated on the basis of 1 / 50 of the maximum tolerated dose)

[0054] Low concentration group: 2.19mg / kg (calculated on the basis of 1 / 100 of the maximum tolerated dose)

[0055] Positive control group: 8-MOP (8-methoxy psoralen, China National Institute of Pharmaceutical and Biological Products) Negative control group: 2.5% hydroquinone blank control group; normal saline

[0056] 2.2. Establishment o...

experiment example 3

[0060] Experimental Example 3. Effects of Butycin on the Immune System of Mice

[0061] 3.1. Experimental scheme

[0062] 3.1.1. Experimental model: Culture Kunming newborn mouse splenocytes.

[0063] 3.1.2. Animal source: provided by Xinjiang Experimental Animal Center.

[0064] 3.1.3. Culture conditions: spleen cells were obtained from the spleen of Kunming newborn mice after trypsinization.

[0065] Add FCS, double antibody and other factors to RPMI1640 medium, 5% CO 2 After culturing at 37°C for 48 hours, different concentrations of drugs and controls were added to determine the relevant analysis indicators.

[0066] 3.2. Results

[0067] Since the current etiological research supports that the pathogenesis of vitiligo is related to the immune system, it is found that there are specific antibodies in the body of patients with vitiligo. The results of research on the effect of butycin on the immune system of mice showed that butycin has inhibitory effects on cellular i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses use of butin and derivatives thereof for preparing drugs having inhibitive effect on an immune system. The use is characterized by preparing drugs having inhibitive effect on an immune system with the butin and the derivatives thereof as active ingredients and a pharmaceutically acceptable carrier.

Description

field of invention [0001] The present invention relates to a new use of a compound and its derivatives, specifically, the use of buteacin and its derivatives in the preparation of medicines for treating pigment metabolism diseases such as vitiligo and white hair. Background technique [0002] Vitiligo is a common localized hypopigmentation skin disease with an incidence rate of 0.5-2.0%. Since the cause and pathogenesis of the disease are not yet clear, it is still difficult to diagnose and difficult to treat internationally. This disease is listed as one of difficult disease by world medical profession. The current drug treatment methods for vitiligo include psoralen combined with UVA therapy, corticosteroid therapy, Kalin combined with UVA therapy, metal elements combined with PUVA therapy, phenylalanine combined with UVA therapy and traditional Chinese medicine therapy. Vernonia anthelmintica Willd is the achene of Vernonia anthelmintica Willd. Harvest when the fruit is...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/353A61P35/00A61P37/06A61P17/00A61P3/00A61P43/00
Inventor 尚靖徐建国于鲁海孙力李建红
Owner 尚靖